Overview

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Status:
Terminated
Trial end date:
2017-10-16
Target enrollment:
Participant gender:
Summary
Approximately 30% of patients who are candidates for bone marrow transplants do not have an HLA-matched, or close to matched, donor available. For this reason, doctors have been testing ways to make transplants from HLA-partially matched donors as safe and effective as transplants from HLA-matched donors. This study is being done to test the safety and the treatment results of a specific kind of transplant. In this transplant, blood from two donors will be used. Each donor will share one half of your HLA type. Blood from both donors will be transplanted at the same time.
Phase:
N/A
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Antilymphocyte Serum
Fludarabine
Fludarabine phosphate
Melphalan
Thiotepa
Vidarabine